[Pubmed] Mitochondrial disorders as a mechanism for the development of obese Sarcopenia

[RSS-Bot]

Diabetol Metab Syndr. 2023 Nov 6;15(1):224. doi: 10.1186/s13098-023-01192-w.

ABSTRACT

Obese sarcopenia is a severe and prevalent disease in an aging society. Compared to sarcopenia alone, the development and advanced stage of obesity sarcopenia is faster and more severe. Diagnosis of the cause of adipocyte accumulation is also more complicated; however, no effective pharmacological treatment is available. Chronic inflammation is one of the causes of sarcopenia, and obese patients, who are more likely to develop chronic inflammation, may simultaneously suffer from obesity and sarcopenia. Mitochondrial metabolic disorders have been more easily observed in the tissue cells of patients with obesity and sarcopenia. Mitochondrial metabolic disorders include abnormal mtDNA release, mitochondrial autophagy, and dynamic mitochondrial disorders. Therefore, this review will reveal the mechanism of development of obesity myasthenia gravis from the perspective of mitochondria and discuss the currently existing small-molecule drugs.

PMID:37926816 | DOI:10.1186/s13098-023-01192-w


Source: https://pubmed.ncbi.nlm.nih.gov/3792681 ... t6+86293ac